| Literature DB >> 34795341 |
Kumiko Taira1, Tomonori Kawakami2, Sujithra Kaushaliya Weragoda3, H M Ayala S Herath2, Yoshinori Ikenaka4,5, Kazutoshi Fujioka6, Madhubhani Hemachandra7, Nirmalie Pallewatta8, Yoshiko Aoyama9, Mayumi Ishizuka4, Jean-Marc Bonmatin10, Makiko Komori11.
Abstract
Neonicotinoids are systemic insecticides used since the 1990's , that possess renal tubular toxicity. We conducted a field-based descriptive study in the North Central Dry-zone of Sri Lanka, where chronic kidney disease (CKD) of unknown etiology has been increasing since the 1990's. To elucidate the relationship between renal tubular dysfunctions and urinary neonicotinoids concentrations, we collected spot urine samples from15 CKD patients, 15 family members, and 62 neighbors in 2015, analyzed two renal tubular biomarkers, Cystatin-C and L-FABP, quantified seven neonicotinoids and a metabolite N-desmethyl-acetamiprid by LC-MS/MS; and we investigated their symptoms using a questionnaire. Cystatin-C and L-FABP had a positive correlation (p < 0.001). N-Desmethyl-acetamiprid was detected in 92.4% of the urine samples, followed by dinotefuran (17.4%), thiamethoxam (17.4%), clothianidin (9.8%), thiacloprid and imidacloprid. Dinotefuran and thiacloprid have never been registered in Sri Lanka. In High Cystatin-C group (> 70 μg/gCre, n = 7), higher urinary concentration of dinotefuran (p = 0.009), and in Zero Cystatin-C group (< LOQ, n = 7), higher N-desmethyl-acetamiprid (p = 0.013), dinotefuran (p = 0.049), and thiacloprid (p = 0.035), and more complaints of chest pains, stomachache, skin eruption and diarrhea (p < 0.05) were found than in Normal Cystatin-C group (n = 78). Urinary neonicotinoids may be one of the potential risk factors for renal tubular dysfunction in this area.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34795341 PMCID: PMC8602289 DOI: 10.1038/s41598-021-01732-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Clinical features of CKDu in Sri Lanka.
| 1. The ratio of male and female is 2.4–3:1, typically male farmers, 40–60 years old, engaged in rice production for more than 10 years in the same area, and are usually poor, but also observed among women and young children |
| 2. The distribution of patients is patchya.. In the urban area with a clean water supply, the prevalence of CKDu is low and in the agricultural areas with ground water use, it is high |
| 3. Hypertension and edema are only seen in the advance stages |
| 4. Urine is hypotonic with β2-microgloburin; and renal pathological change is mainly in tubules and interstitial tissues |
aFor example, in a village, 2–3% of population no less than 18 years old are affected by CKDu, but in the neighboring village only a few kilometers away, no patients are found.
Comparison of the characteristics of three urinary biomarkers.
| Biomarker | Creatinine | Cystatin-C | L-FABP |
|---|---|---|---|
| Molecular weight | 113.1 g/mole | 13 kDa, protein | 14–15 kDa, protein |
| Origin, physiological | Skeletal muscle | Cell | Liver |
| Origin, pathological | Proximal tubules under ischemia and oxidative stress | ||
| Secretion in nephron | Glomerulus | Glomerulus | Glomerulus, pathological proximal tubules |
| Reabsorption in nephron | No | Proximal tubule | Normal proximal tubules |
| Reference value | Not determined | ≦70 μg/g Cre | ≦8.4 μg/g Cre |
Typical symptoms of neonicotinoid intoxication.
| Acute exposure | Subacute and chronic exposure | |
|---|---|---|
| Cardiovascular | Tachycardia or bradycardia; hypertension or hypotension | Chest pains; palpitation; electrocardiographic abnormalities |
| CNS | Low GCS or unconsciousness; sleepiness; dizziness; convulsion; excitation | Headache; finger tremor, recent memory loss; dizziness upon standing; sleeplessness; agitation; fear; anger; abnormal behavior; altered consciousness; dreamy state; sudden change of senses of smell; auditory or visual hallucinations, |
| Respiratory | Dyspnea or tachypnea; cough; cyanosis; respiratory arrest | Cough |
| Gastrointestinal | Nausea; vomiting; stomachache; oral-esophageal-gastric erosion | Stomachache; appetite loss; constipation or diarrhea, |
| Secretion | Diaphoresis or anhidrosis; excessive discharge of saliva and bronchial secretion/mouth dryness | |
| Pupil | Mydriasis or miosis; abnormal light reflex | Abnormal light reflex |
| Body temperature | Fever or low body temperature | Fever (> 37°c) |
| Skeletal muscle | Muscle weakness or spasm; high creatine kinase | General fatigue; shoulder stiffness; muscle pain or spasm or weakness |
| Others | Metabolic acidosis; leukocytoclastic vasculitis; renal and hepatic disfunction | Oliguria; edema; low or high urine volume; increase of urinary cystatin-c; skin eruptions or itching; reduced or increased body weight |
The geographic data of the sampling area in this study.
| Sampling area (Divisional Secretariat) | Wilgamuwa | Anuradhapura city |
|---|---|---|
| Province | Central | North Central |
| District | Matale | Anuradhapura |
| Population of the district | 484,531 in 2012 | 854,602 in 2013 |
| The percentage of households reporting at least one member diagnosed with CKD who resided in the household between 2009 and 2018 in the district | 16.7% | 18.9% |
The MRM transits, retention times, recovery % and LOQ of seven neonicotinoids and DMAP.
| Name | MRM (m/z) | RT (min) | Recovery rate (%) | LOQ (μg/L) |
|---|---|---|---|---|
| Imidacloprid | 256.00 > 209.05 | 17.3 | 87.0 ± 2.7 | 0.5 |
| Acetamiprid | 223.00 > 126.00 | 16.2 | 80.2 ± 2.9 | 0.05 |
| Nitenpyram | 271.00 > 126.05 | 8.9 | 88.6 ± 4.6 | 0.5 |
| Thiacloprid | 252.90 > 126.05 | 19.1 | 92.9 ± 1.8 | 0.05 |
| Thiamethoxam | 291.90 > 211.00 | 14.0 | 116.7 ± 7.9 | 0.125 |
| Clothianidin | 249.90 > 132.05 | 16.1 | 91.8 ± 3.7 | 0.125 |
| Dinotefuran | 203.00 > 129.10 | 8.2 | 92.6 ± 2.8 | 0.125 |
| DMAP | 208.90 > 126.05 | 15.2 | 87.6 ± 5.4 | 0.05 |
MRM multiple reaction monitoring; RT retention time; LOQ limit of quantification; DMAP N-desmethyl acetamiprid.
Demographic data of 92 participants.
| May 2015 | Dec 2015 | ||||||
|---|---|---|---|---|---|---|---|
| CKDs | Families | Neighbors | CKDs | Families | Neighbors farmers | Neighbors not farmers | |
| N | 9 | 5 | 19 | 6 | 10 | 12 | 31 |
| Male | 7 | 2 | 10 | 4 | 2 | 5 | 8 |
| Age (mean ± SD) | 50.0 ± 10.0 | 25.6 ± 15.5 | 33.4 ± 16.2 | 58.5 ± 14.0 | 51.0 ± 11.5 | 52.3 ± 9.0 | 38.9 ± 19.2 |
| Wilgamuwa | 5 | 1 | 2 | 0 | 0 | 0 | 0 |
| Anuradhapura | 4 | 4 | 17 | 6 | 10 | 12 | 31 |
| Active farmer | No data | No data | No data | 0 | 5 | 12 | 0 |
| Retired farmer | No data | No data | No data | 5 | 0 | 0 | 0 |
| Not farmer | No data | No data | No data | 1 | 5 | 0 | 31 |
CKDs: CKD patients; Families: CKD patients’ family members; Neighbors: healthy individuals living in Wilgamuwa and Anuradhapura.
Figure 1Relationship between L-FABP and Cystatin-C of participants. Black squares stand for CKD patients, small black circles stand for other participants. Broken lines indicate the reference value of markers, L-FABP 8.4 μg/g Cre and Cystatin-C 70 μg/g Cre. Log10(L-FABP) = 0.536 × Log10(Cystatin-C) + 0.0193, r = 0.75, p < 0.001.
Demographic data of three groups classified by Urinary Cystatin-C concentration.
| Group | Zero CysC | Normal CysC | High CysC | ||
|---|---|---|---|---|---|
| Cystatin-C (μg/g Cre) | < LOQb | LOQ-70 | > 70 | ||
| N | 7 | 78 | 7 | ||
| Male/female | 1/6 | 32/46 | 6/1 | 0.16 | |
| CKDs | 0 | 10 (7/3) | 5 (4/1) | 0.31 | |
| Families | 1 (0/1) | 14 (4/10) | 0 | ||
| Neighbors | 6 (1/5) | 54 (21/33) | 2 (2/0) | ||
| Age (mean ± SD) | 36.3 ± 15.3 | 41.9 ± 17.6 | 61.1 ± 10.2 | 0.45 | |
| UACR > 30 | 0% | 1.3% | 28.6% | 0.76 | |
| Urine blood positive | 71.4% | 43.6% | 57.1% | 0.17 | 0.49 |
| Urine pH (mean ± SD) | 5.57 ± 0.67 | 5.72 ± 0.55 | 5.80 ± 0.45 | 0.50 | 0.76 |
| Urine Creatinine | |||||
| (mean ± SD, mg/dL) | 18.7 ± 8.1 | 105.2 ± 68.4 | 74.4 ± 44.9 | 0.25 | |
| Urine L-FABP | |||||
| (mean ± SD, μg/g Cre) | 4.72 ± 4.91 | 1.99 ± 3.08 | 65.9 ± 54.1 | 0.056 | |
| Low Urine volume (self-reported) | 14.3% | 25.6% | 28.6% | 0.50 | 0.87 |
| High urine volume (self-reported) | 28.6% | 41.0% | 57.1% | 0.52 | 0.41 |
| Glomerular damage | No | No | Yes | ||
| Proximal tubule reabsorption | Conserved | Conserved | Impaired | ||
| Proximal tubule damage | Likely | Not likely | Highly damaged | ||
| Distal tubule reabsorption | Impaired | Conserved | Impaired | ||
| CKDu | Not likely | Not likely | Likely | ||
| Other CKD | Not likely | Not likely | Possibly | ||
| Tubulointerstitial nephritis | Likely | Not likely | Possibly | ||
aChi-square test for categorical data, and t-test for numerical data; bLOQ of Cystatin-C was 0.01 μg/L.
Concentration and detection rate more than LOQ of urinary neonicotinoids and DMAP.
| Neonicotinoid | > LOQ (%) | Mean ± SD | Selected percentile (uncorrecteda, Cre-adjustedb) | Max | ||||
|---|---|---|---|---|---|---|---|---|
| GMc | 25th | 50th | 75th | 95th | ||||
| DMAP | 92.4 | 0.88 ± 1.09 | 0.46 | 0.23, 0.20 | 0.52, 0.60 | 0.99,1.61 | 2.49, 7.37 | 6.63, 21.5 |
| Dinotefuran | 17.4 | 0.10 ± 0.28 | 0.09 | < LOQ | < LOQ | < LOQ | 0.62, 0.74 | 1.65, 11.5 |
| Thiamethoxam | 17.4 | 0.19 ± 0.80 | 0.09 | < LOQ | < LOQ | < LOQ | 0.83, 1.42 | 7.02, 7.10 |
| Clothianidin | 9.8 | 0.05 ± 0.15 | 0.07 | < LOQ | < LOQ | < LOQ | 0.28, 0.50 | 0.81, 3.61 |
| Thiacloprid | 3.3 | 0.01 ± 0.05 | 0.03 | < LOQ | < LOQ | < LOQ | < LOQ | 0.31, 1.18 |
| Imidacloprid | 2.2 | 0.11 ± 0.58 | 0.26 | < LOQ | < LOQ | < LOQ | < LOQ | 5.47, 5.44 |
| Acetamiprid | 0 | < LOQ | < LOQ | < LOQ | < LOQ | < LOQ | < LOQ | < LOQ |
| Nitenpyram | 0 | < LOQ | < LOQ | < LOQ | < LOQ | < LOQ | < LOQ | < LOQ |
GM geometric mean; aUnit of uncorrected concentration is ug/L; bunit of creatinine-adjusted concentration is μg/g Cre.
Concentration and detection rate more than LOQ of urinary neonicotinoids and DMAP (μg/g Cre) in each class of urinary creatinine-adjusted Cystatin-C concentration.
| Zero CysC | Normal CysC | High CysC | A vs B | B vs C | Correlation Coefficientb | |
|---|---|---|---|---|---|---|
| DMAP | 71.4% | 96.2% | 85.7% | 0.21 | ||
| Dinotefuran | 28.6% | 15.4% | 28.6% | 0.38 | 0.37 | |
| Thiamethoxam | 42.9% | 20.5% | 0% | 0.17 | 0.18 | |
| Imidacloprid | 0% | 2.6% | 14.3% | 0.67 | 0.11 | |
| Clothianidin | 28.6% | 16.7% | 0% | 0.43 | 0.24 | |
| Thiacloprid | 14.3% | 2.6% | 0% | 0.11 | 0.67 | |
| DMAP | 1.90 ± 2.31 | 0.81 ± 0.92 | 0.58 ± 0.68 | 0.53, 0.44 | − 0.08, 0.44 | |
| Dinotefuran | 0.24 ± 0.45 | 0.07 ± 0.19 | 0.33 ± 0.63 | 0.01, 0.92 | ||
| Thiamethoxam | 0.10 ± 0.13 | 0.21 ± 0.87 | 0 | 0.73, 0.26 | IC, 0.25 | − 0.04, 0.73 |
| Imidacloprid | 0 | 0.08 ± 0.62 | 0.01 ± 0.03 | IC, 0.67 | 0.78, 0.12 | − 0.014, 0.89 |
| Clothianidin | 0.15 ± 0.31 | 0.04 ± 0.13 | 0 | 0.057, 0.33 | IC, 0.25 | − 0.05, 0.64 |
| Thiacloprid | 0.04 ± 0.12 | 0.01 ± 0.04 | 0 | IC, 0.67 | − 0.03, 0.79 | |
| DMAP | 9.20 ± 8.70 | 1.16 ± 1.98 | 0.98 ± 1.08 | 0.82, 0.99 | − 0.06, 0.57 | |
| Dinotefuran | 2.12 ± 4.32 | 0.07 ± 0.19 | 0.42 ± 0.85 | − 0.02, 0.88 | ||
| Thiamethoxam | 0.61 ± 0.98 | 0.26 ± 0.92 | 0 | 0.34, 0.14 | IC, 0.25 | − 0.05, 0.65 |
| Imidacloprid | 0 | 0.04 ± 0.24 | 0.01 ± 0.03 | IC, 0.67 | 0.79, 0.12 | − 0.01, 0.89 |
| Clothianidin | 0.63 ± 1.35 | 0.05 ± 0.15 | 0 | IC. 0.25 | − 0.04, 0.73 | |
| Thiacloprid | 0.17 ± 0.45 | 0.004 ± 0.031 | 0 | IC, 0.67 | − 0.02, 0.84 | |
IC: incalculable; aFor > LOQ%, Chi-square test, for neonicotinoids concentration, t test, Mann–Whitney U test (2-tailed); bPearson correlation Coefficient between neonicotinoids/DMAP and Cystatin C in A, B and C, R, p value.
Relationship between CKD diagnosis, high urine Cystatin-C, very low urine Cystatin-C, urine neonicotinoids/DMAP and subjective symptoms related to neonicotinoids exposure.
| CKD | High CysC | Zero CysC | urine neonicotinoids | subjective symptoms | |
|---|---|---|---|---|---|
CKD diagnosed at hospital | |||||
High CysC (> 70 μg/gCre) | + + + | none | |||
Zero CysC (< LOQ) | ± | ||||
urine neonicotinoid (uncorrected) | + + | + | + | ||
| subjective symptoms | + + + | - | + + | + + + |
+ + + : p < 0.001, + + : p < 0.01, + : p < 0.05, ± : p < 0.5.
Figure 2Candidate mechanism of lower urinary neonicotinoids (NNs) concentration in higher urinary Cystatin-C participants and in very low urinary Cystatin-C participants. This figure was originally made by Kumiko Taira with Power Point, following the software’s attribution guidelines.